Investing in Drug Safety Monitoring could Avoid Complications - and Save Medical Costs

Increased investment in "pharmacovigilance surveillance" - systems to proactively monitor safety problems with new medications - has the potential to avoid harmful drug effects while lowering healthcare costs, according to a study in the June issue of Medical Care. The journal is published by Wolters Kluwer.

Three recent cases in which serious safety issues led to medication withdrawals illustrate the potential return on investment of building a more effective pharmacovigilance surveillance system, according to the report by Krista F. Huybrechts, PhD, of Brigham and Women's Hospital, Boston, and colleagues. They write, "Our analyses demonstrate a pivotal and economically justifiable role for active pharmacovigilance in protecting the health of the public."

Detecting 'Early Signals' Could Have Avoided Drug Adverse Events The researchers analyzed three important instances of major adverse drug events that led to medications being taken off the market. In each case, early signs of medication safety hazards could have been picked up from clinical trials and/or spontaneous reports. However, these problems went unrecognized, with continued patient exposure leading to avoidable complications and costs.

The highest-profile example was the "COX2 inhibitor" rofecoxib (marketed as Vioxx), widely used for arthritis treatment. In more than five years on the market, approximately 105 million rofecoxib prescriptions were filled by US patients. Over time, it became clear that this medication was associated with a substantially increased risk of acute myocardial infarction (heart attack).

But this adverse effect could have been detected as early as one year after rofecoxib appeared on the market, based on analyses of actual healthcare utilization data available at the time. Early signal detection based on active pharmacovigilance surveillance could have averted 27,500 myocardial infarctions, Dr. Huybrechts and colleagues estimate.

In the other two cases, active surveillance might have avoided 190 cases of a rare but serious complication called rhabdomyolysis in patients taking the cholesterol-lowering drug cerivastatin (Baycol); and 264 cases of liver failure attributable to the diabetes drug troglitazone (Rezulin). The authors note that there were questions about the true benefits of all three drugs, and that other treatment options were available.

Earlier recognition of these safety issues could have resulted in savings in direct medical costs of $773 to $884 million for rofecoxib, $3 to $10 million for cerivastatin, and $38 to $63 million for troglitazone. Those figures don't consider indirect financial costs such as missed work time - not to mention the human costs of experiencing a potentially serious complication.

The researchers believe their findings illustrate the potential return on investment in pharmacovigilance surveillance programs--a function that is historically "overburdened and under-funded." In the United States, investment in pharmacovigilance is estimated at about $42.5 million per year.

While the frequency of new drug safety concerns is unpredictable, "It is clear that major adverse drug events are not rare," Dr. Dr. Huybrechts and coauthors write. "Investment in active drug surveillance offers protection against the occurrence of such events, which are bound to recur."

Huybrechts KF, Desai RJ, Park M, Gagne JJ, Najafzadeh M, Avorn J.
The Potential Return on Public Investment in Detecting Adverse Drug Effects.
Med Care. 2017 Jun;55(6):545-551, doi: 10.1097/MLR.0000000000000717.

Most Popular Now

HIMSS IMPACT Big Data in Medicine

20 - 21 Novemebr 2017, Potsdam, Germany. Big Data looks set to become a game-changer for healthcare and is likely to have a groundbreaking effect in all areas - from health...

New App Uses Smartphone Selfies to Scree…

Pancreatic cancer has one of the worst prognoses - with a five-year survival rate of 9 percent - in part because there are no telltale symptoms or non-invasive screening tools...

New Diagnostic Tool Spots First Signs of…

Researchers have developed the first tool that can diagnose Parkinson's disease when there are no physical symptoms, offering hope for more effective treatment of the condition. There are currently no...

Nurses Becoming e-Nurses by Using Patien…

The ambitions of NHS Digital’s e-nursing week and the Royal College of Nursing's (RCN) 'Every nurse an e-nurse' campaign are being realised by nurses across the UK, who are seeing...

Google Glass App Helps Autistic Children…

A prototype software application, to be used with the optical head-mounted display Google Glass, has been designed as a social-skills coach for children with autism spectrum disorder (ASD). A new...

Stroke Patient Improvement with a Brain-…

University of Adelaide researchers have shown that it is possible for stroke patients to improve motor function using special training involving connecting brain signals with a computer. In a "proof-of-principle...

eHealth Hub Call: Lean Startup Academy

The Lean Startup Academy is an unique opportunity to mature your business by systematically testing your ideas against the market with the support of experts. The course will help you...

NHS 'Will be Hit by More Cyber Attacks'

Concern about NHS cyber security has increased following the WannaCry attack and healthcare management professionals expect it to come under further attack from "organised hacktivists", according to a new survey...

Philips Innovations at IFA 2017 Put Cons…

At this year's Internationale Funkausstellung (IFA) in Berlin, Germany, Royal Philips (NYSE: PHG, AEX: PHIA) showcases new products and services that empower consumers to take an active role in managing...

eHealth Hub: Investment Readiness Traini…

eHealth Hub presents to European SMEs the opportunity to take part in upcoming Health Pioneers event (25 October) on new health technology and related investment scene. The day before the...

Adoption of Robotics into a Hospital's D…

VTT Technical Research Centre of Finland studied the implementation of a logistics robot system at the Seinäjoki Central Hospital in South Ostrobothnia. The aim is to reduce transportation costs, improve...